Gleevec or Glivec - Imatinib - Chronic Myeloid Leukemia
''Imatinib was developed in the late 1990s by biochemist Nicholas Lydon, a former researcher for Novartis, and oncologist Brian Druker of Oregon Health and Science University (OHSU). Other major contributions to imatinib development were made by Carlo Gambacorti-Passerini, a physician scientist at University of Milano Bicocca, Italy, John Goldman at Royal Hammersmith Hospital in London, UK, and later on by Charles Sawyers of Memorial Sloan-Kettering Cancer Center who led the clinical trials confirming its efficacy in CML''
Extract from Wikipedia
"Jürg Zimmermann, a medicinal chemist, is the chemical inventor of the compound STI571 also called Gleevec''
Extract from Novartis
SITES
Gleevec by Novartis
Glivec research Today
Gleevec by drugwatch
Imatinib Mesylate by National Cancer Institute
Story of Gleevec
FORUMS
Gleevec (Warning - old messages from 2001 to 2006)
Brain_Gleevec (Warning - old messages from 2001 to 2006)
Gleevec (imatinib mesylate) on Facebook
Glivec research Today
Gleevec by drugwatch
Imatinib Mesylate by National Cancer Institute
Story of Gleevec
FORUMS
Gleevec (Warning - old messages from 2001 to 2006)
Brain_Gleevec (Warning - old messages from 2001 to 2006)
Gleevec (imatinib mesylate) on Facebook
VIDEOS
BCR-ABL and Gleevec - October 2012
Imatinib therapy for CML (Dr. Susan Branford) - April 2010
Gleevec’s effects on Tyrosine Kinase - June 2007
Cardiac Events with Gleevec - February 2007
BCR-ABL and Gleevec - October 2012
Imatinib therapy for CML (Dr. Susan Branford) - April 2010
Gleevec’s effects on Tyrosine Kinase - June 2007
Cardiac Events with Gleevec - February 2007
ARTICLES
Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects.
November 8, 2012, PublMed
Is Imatinib Still an Acceptable First-Line Treatment for CML in Chronic Phase?
October 12, 2012, Cancer Network
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
June 1, 2012, Haematalogica
Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects.
November 8, 2012, PublMed
Is Imatinib Still an Acceptable First-Line Treatment for CML in Chronic Phase?
October 12, 2012, Cancer Network
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
June 1, 2012, Haematalogica
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
February 7, 2012, Haematologica
February 7, 2012, Haematologica
The Apothecary Shops Incorporates Innovative Technology Into Patient Medication Reminders
December 19, 2011, PRNewswire
Imatinib is receptive to a collaboration
October 13, 2011, Journal Blood
Leukemia Patients Taking Gleevec Achieve ‘Normal’ Death Rate
March 22, 2011, HealthDay News
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
December 15, 2010, CMLHope.com
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
December 2, 2010, Dovepress
Important correction of drug information about Gleevec
September 2010, Novartis
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death
March 31, 2010, Mendeley
Researcher Behind the Drug Gleevec
November 2009, The New York Times
GIST Q&A with Dr. Peter Reichardt
2007 by Life Raft Group
Gleevec (imatinib mesylate) - Advisories, Warnings and Recalls for Health Professionals
September 21, 2006, Health Canada
Indications for Imatinib Mesylate Therapy and Clinical Management
March 4, 2004, The Oncologist
Powerful Anti-Cancer Drug Emerges from Basic Biology
May 8, 2001, The New York Times
December 19, 2011, PRNewswire
Imatinib is receptive to a collaboration
October 13, 2011, Journal Blood
Leukemia Patients Taking Gleevec Achieve ‘Normal’ Death Rate
March 22, 2011, HealthDay News
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
December 15, 2010, CMLHope.com
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
December 2, 2010, Dovepress
Important correction of drug information about Gleevec
September 2010, Novartis
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death
March 31, 2010, Mendeley
Researcher Behind the Drug Gleevec
November 2009, The New York Times
GIST Q&A with Dr. Peter Reichardt
2007 by Life Raft Group
Gleevec (imatinib mesylate) - Advisories, Warnings and Recalls for Health Professionals
September 21, 2006, Health Canada
Indications for Imatinib Mesylate Therapy and Clinical Management
March 4, 2004, The Oncologist
Powerful Anti-Cancer Drug Emerges from Basic Biology
May 8, 2001, The New York Times
